Compare Eaton Corporation plc (ETN) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Nuvalent Inc — how do they compare? Eaton Corporation plc trades at $393.88 (market cap $160.31B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Eaton Corporation plc is far larger — about 16.3× Nuvalent Inc's market cap, and Eaton Corporation plc pays a 1.07% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| ETN | NUVL | |
|---|---|---|
Market Cap | $160.31B | $9.81B |
Sector | Technology | Technology |
52-Week High | $435.78 | $123.96 |
52-Week Low | $315.82 | $72.16 |
Enterprise Value | $181.40B | $8.52B |
Dividend Yield | 1.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $404.20, down 2.72% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding expectations. Analyst consensus is overwhelmingly positive with 25 buy ratings and a $449.50 price target. Recent news highlights growth in AI data center power infrastructure and a new sustainability report showing 40% emissions reduction.
ETN's outlook remains favorable due to robust demand in data center and aerospace markets, though elevated valuation multiples (P/E 40.4) pose a risk if growth moderates. The stock offers upside to consensus targets but faces execution risks from large 2026 investing outflows. Dividend payments provide income support with the next $1.10 distribution scheduled for May 29, 2026.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
